Featured Research

from universities, journals, and other organizations

New Alzheimer's Treatment Completes First Phase Of Testing

Date:
January 28, 2008
Source:
Purdue University
Summary:
A molecule designed by a Purdue University researcher to stop the debilitating symptoms of Alzheimer's disease has been shown in its first phase of clinical trials to be safe and to reduce biomarkers for the disease. CoMentis, the pharmaceutical company developing the drug, announced completion of its Phase 1 study of a treatment based on the molecule. Results from the study indicate that the treatment is safe and well tolerated.

Arun Ghosh, at right, a Purdue professor of chemistry and medicinal chemistry, and graduate student Xiaoming Xu discuss the structure of an enzyme inhibitor designed to treat Alzheimer's disease.
Credit: Purdue News Service file photo/David Umberger

A molecule designed by a Purdue University researcher to stop the debilitating symptoms of Alzheimer's disease has been shown in its first phase of clinical trials to be safe and to reduce biomarkers for the disease.

CoMentis, the pharmaceutical company developing the drug, announced on Jan. 7 completion of its Phase 1 study of a treatment based on the molecule. Results from the study indicate that the treatment is safe and well tolerated.

Arun Ghosh, a Purdue professor with a dual appointment in the departments of chemistry and medicinal chemistry and molecular pharmacology, designed the molecule that could allow for intervention in the disease's early stages.

The molecule, called a beta-secretase inhibitor, prevents the first step in a chain of events that leads to amyloid plaque formation in the brain. This plaque formation creates fibrous clumps of toxic proteins that are believed to cause the devastating symptoms of Alzheimer's.

The study of 48 healthy volunteers showed dose-related reduction in plasma amyloid beta, a protein believed to be a key biomarker of Alzheimer's. Results showed a single dose of the drug produced a greater than 60 percent reduction of the biomarker. Subjects received one of six different doses or a placebo, and the study measured levels of the therapeutic drug and levels of the biomarker in the bloodstream.

CoMentis plans to begin a phase II clinical study of the drug, oral CTS-21166, in Alzheimer's patients in 2008.

Alzheimer's disease usually begins after age 60, and the risk increases with age. According to the National Institute on Aging, about 5 percent of men and women ages 65-74 have Alzheimer's disease, and nearly half of those 85 and older may have the disease, for which there is currently no effective treatment.

There is no conclusive test for Alzheimer's. Doctors are able to diagnose "probable Alzheimer's" through a combination of medical tests that include blood tests and brain scans and evaluations of brain function.

"The phase I clinical results are very exciting," Ghosh said. "We hope that this beta-secretase inhibitor drug will be one of the first disease modifying treatments that stops or reverses the symptoms of Alzheimer's disease."


Story Source:

The above story is based on materials provided by Purdue University. Note: Materials may be edited for content and length.


Cite This Page:

Purdue University. "New Alzheimer's Treatment Completes First Phase Of Testing." ScienceDaily. ScienceDaily, 28 January 2008. <www.sciencedaily.com/releases/2008/01/080123101629.htm>.
Purdue University. (2008, January 28). New Alzheimer's Treatment Completes First Phase Of Testing. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2008/01/080123101629.htm
Purdue University. "New Alzheimer's Treatment Completes First Phase Of Testing." ScienceDaily. www.sciencedaily.com/releases/2008/01/080123101629.htm (accessed September 17, 2014).

Share This



More Mind & Brain News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com
'Magic Mushrooms' Could Help Smokers Quit

'Magic Mushrooms' Could Help Smokers Quit

Newsy (Sep. 11, 2014) In a small study, researchers found that the majority of long-time smokers quit after taking psilocybin pills and undergoing therapy sessions. Video provided by Newsy
Powered by NewsLook.com
'Fat Shaming' Might Actually Cause Weight Gain

'Fat Shaming' Might Actually Cause Weight Gain

Newsy (Sep. 11, 2014) A study for University College London suggests obese people who are discriminated against gain more weight than those who are not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins